Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 7, 2014, Pages 1078-1087

  van Rhijn, Bas W G ^a   Catto, James W ^b   Goebell, Peter J ^c   Knüchel, Ruth ^d   Shariat, Shahrokh F ^e   van der Poel, Henk G ^a   Sanchez Carbayo, Marta ^f   Thalmann, George N ^g   Schmitz Dräger, Bernd J ^h   Kiemeney, Lambertus A ⁱ  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CIC BIOGUNE   (Spain)

^g UNIVERSITY OF BERN   (Switzerland)

^h Schön Klinik   (Germany)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder; Cancer; Marker; Molecular; Reproducibility; Urothelial

Indexed keywords

CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; METHOTREXATE; MINICHROMOSOME MAINTENANCE PROTEIN 2; MOLECULAR MARKER; PROTEIN P53; SURVIVIN; TUMOR MARKER; VINBLASTINE; BIOLOGICAL MARKER;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE REGULATION; CHROMOSOME 9; CHROMOSOME DELETION; CLINICAL PRACTICE; CYSTECTOMY; DOWN REGULATION; FOLLOW UP; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; LYMPH VESSEL METASTASIS; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REPRODUCIBILITY; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION; BLADDER TUMOR; GENETICS; METABOLISM; PATHOLOGY;

BIOLOGICAL MARKERS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84920728089     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.07.002     Document Type: Review

References (66)

1. GLOBOCAN Cancer incidence, mortality and prevalence worldwide in 2012 2012, International Agency for Research on Cancer, Lyon, France, http://globocan.iarc.fr.
2. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477.
3. Van Rhijn B.W., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009, 56:430-442.
4. Babjuk M., Burger M., Zigeuner R., et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder-update 2013. Eur Urol 2013, 64:639-653.
5. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., Hauser R. The health economics of bladder cancer. Pharmacoeconomics 2003, 21:1315-1330.
6. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
7. Stenzl A., Cowan N.C., De Santis M., et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011, 59:1009-1018.
8. Van der Meijden A., Sylvester R., Collette L., Bono A., Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 2000, 164:1533-1537.
9. van Rhijn B.W., van Leenders G.J.L.H., ECM Ooms, et al. The pathologist[U+05F3]s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 2010, 57:1052-1057.
10. Zieger K., Wolf H., Olsen P.R., Hojgaard K. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. BJU Int 2000, 85:824-828.
11. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., Palou J., Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000, 163:73-78.
12. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Palou J., Algaba F., Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164:680-684.
13. Lammers R.J.M., Sylvester R.J., Lee C.T., Witjes J.A. NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved?. Urol Clin North Am 2013, 40:155-164.
14. Kurth K.H., Sylvester R.J. Prognostic factors in non-muscle invasive bladder tumors. I: clinical prognostic factors: a review of the experience of the EORTC Genito-Urinary group. II: biologic prognostic markers. Eur Urol Suppl 2007, 6:789-799.
15. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008, 53:992-1001.
16. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998, 160:645-659.
17. Duggan B.J., McKnight J.J., Williamson K.E., et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 2003, 9:1240-1247.
18. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese. Carcinogenesis 2006, 27:361-373.
19. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21:1912-1921.
20. Burger M., van der Aa M.N., van Oers J.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008, 54:835-843.
21. Shariat S.F., Ashfaq R., Sagalowsky A.I., Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007, 177:481-487.
22. Moonen P.M., van Balken Ory B., Kiemeney L.A., Schalken J.A., Witjes J.A. Prognostic value of P53 for high risk superficial bladder cancer with long-term follow-up. J Urol 2007, 177:80-83.
23. Schultz I.J., Wester K., Straatman H., et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007, 51:416-422.
24. Burger M., Denzinger S., Hartmann A., Wieland W.F., Stoehr R., Obermann E.C. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer 2007, 96:1711-1715.
25. Dyrskjøt L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003, 33:90-96.
26. Dyrskjøt L., Zieger K., Real F.X., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007, 13:3545-3551.
27. Lamm D., Persad R., Brausi M., et al. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 2014, 191:20-27.
28. Kunju L.P., You L., Zhang Y., Daignault S., Montie J.E., Lee C.T. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008, 180:1928-1932.
29. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788.
30. Yates D.R., Rehman I., Abbod M.F., et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007, 13:2046-2053.
31. Karam J.A., Shariat S.F., Hsieh J.T., Knowles M.A. Genomics: a preview of genomic medicine. BJU Int 2008, 102:1221-1227.
32. van Rhijn B.W., Zuiverloon T.C.M., Vis A.N., et al. Molecular grade (FGFR3/MIB-1) and EORTC risk-scores are predictive in primary non-muscle invasive bladder cancer. Eur Urol 2010, 58:433-441.
33. Goebell P.J., Groshen S., Schmitz-Dräger B.J., et al. P53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 2010, 28:377-388.
34. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005, 6:678-686.
35. Hernández S., López-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
36. van Oers J.M., Zwarthoff E.C., Rehman I., et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009, 55:650-657.
37. Shariat S.F., Zlotta A.R., Ashfaq R., Sagalowsky A.I., Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007, 20:445-459.
38. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
39. Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M.K., et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
40. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205.
41. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012, 366:1477-1488.
42. Margulis V., Lotan Y., Karakiewicz P.I., et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009, 101:114-119.
43. Shariat S.F., Chade D.C., Karakiewicz P.I., et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010, 183:68-75.
44. Shariat S.F., Chade D.C., Karakiewicz P.I., et al. Combination of multiple molecular markers can improve prognostication in patients with organ confined bladder cancer. J Urol 2012, 187:457-462.
45. Fleischmann A., Thalmann G.N., Markwalder R., Studer U.E. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005, 23:2358-2365.
46. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007, 51:137-149.
47. Shariat S.F., Passoni N., Bagrodia A., et al. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int 2014, 113:70-76.
48. Lotan Y., Bagrodia A., Passoni N., et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol 2013, 64:465-471.
49. Shariat SF, Karakiewicz PI, Droller MJ, et al. Molecular markers for bladder cancer staging and prognosis. 2nd International Consultation on Bladder Cancer, Vienna; 2nd ed. 2012. p. 207-32.
50. Sanchez-Carbayo M., Socci N.D., Kirchoff T., et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 2007, 13:3215-3220.
51. Stadler W.M., Lerner S.P., Groshen S., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011, 29:3443-3449.
52. Sanchez-Carbayo M., Socci N.D., Lozano J., Saint F., Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789.
53. Lindgren D., Frigyesi A., Gudjonsson S., et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010, 70:3463-3472.
54. Smith S.C., Baras A.S., Dancik G., et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011, 12:137-143.
55. Lauss M., Ringnér M., Höglund M. Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin Cancer Res 2010, 16:4421-4433.
56. Sjödahl G., Lövgren K., Lauss M., et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 2013, 183:681-691.
57. van Rhijn B.W., van der Kwast T.H., Kakiashvili D., et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 2010, 106:206-211.
58. McShane L.M., Aamodt R., Cordon-Cardo C., et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 2000, 6:1854-1864.
59. Wild P.J., Herr A., Wissmann C., et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005, 11:4415-4429.
60. Lindgren D., Liedberg G., Andersson A., et al. Molecular characterization of early stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006, 25:2685-2696.
61. Shariat S.F., Lotan Y., Vickers A., et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010, 28:389-400.
62. Goebell P.J., Groshen S.L., Schmitz-Drager B.J. Guidelines for development of diagnostic markers in bladder cancer. World J Urol 2008, 26:5-11.
63. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
64. Hayes D.F., Bast R.C., Desch C.E., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466.
65. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013, 31:3133-3140.
66. Colombel M., Heidenreich A., Martinez-Pineiro L., et al. Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial. Eur Urol 2014, 65:509-511.